Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claim that INGREZZA/INGREZZA SPRINKLE increase the risk of depression and suicidal ideation/behavior in patients with Huntington’s disease is directly supported by the label’s Boxed Warning and Warnings and Precautions (5.1), with supporting trial data referenced in the label.
Category Scores
Accurate Statements
INGREZZA/INGREZZA SPRINKLE increase the risk of depression and suicidal ideation/behavior in patients with Huntington’s disease.
Supported by Boxed Warning and Warnings and Precautions (5.1): “VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior…” and “can increase the risk for suicidal ideation and behaviors…”; supporting trial data cited in 6.1 (e.g., depression 4.7% vs 1.6%).
Unsupported Statements
Contradictions
Important Omissions
The AI did not mention the label’s specific patient management instructions in 5.1/17 (e.g., to closely monitor for new/worsening depression or suicidal ideation/behavior, consider discontinuation if unresolved, and evaluate patients expressing suicidal ideation immediately).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core safety claim about increased risk in Huntington’s disease is consistent with the boxed warning and label warnings; however, the response omits label-recommended monitoring/evaluation actions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of label-required/explicit monitoring and management instructions related to depression and suicidal ideation/behavior (5.1 and 17).
Suggested Improvement
Add that patients should be observed for new or worsening depression/suicidal ideation/behavior, consider discontinuation if unresolved, and that Huntington’s disease patients expressing suicidal ideation should be evaluated immediately, as stated in the label.